GRANDPHARMA (00512.HK): RSV Drug GPN01564 Cleared for Phase I Trial
NewTimeSpace News: On 19 November 2026, Grand Pharmaceutical Group Limited (stock code: 00512.HK) announced that GPN01564, a global innovative nebulized inhalation agent independently developed by the Group for the treatment of respiratory syncytial virus (RSV), has been approved by China's National Medical Products Administration (NMPA) to conduct a Phase I clinical trial.
GPN01564 is an inhibitor of the RSV fusion protein (F protein). As a Type I membrane fusion protein, the F protein has emerged as one of the most promising targets for RSV prevention and treatment, combining the unique antigenic epitope conformation of the pre-fusion state with a high capacity to induce neutralizing antibodies. Administered by nebulized inhalation, the product targets the lungs directly rather than requiring systemic delivery, enabling precise, non-invasive dosing with a distinct clinical advantage in medication compliance. Preclinical results indicate favourable druggability, safety and efficacy.
According to the announcement, RSV is a major pathogen responsible for lower respiratory tract infections. In 2019 there were 33 million cases of RSV-caused acute lower respiratory tract infections (ALRTIs) globally, and RSV leads to over 3.6 million hospitalisations among children under five each year, resulting in about 100,000 deaths. China carries one of the highest RSV burdens worldwide, with about 3.5 million RSV-associated ALRTIs in children under five in 2019, over 10% of the global total, and 620,000 to 950,000 hospitalisations, or 17% to 24% of the world figure. Only monoclonal antibodies and vaccines are currently available, and only for prevention in infants, young children and the elderly; there are no specific antiviral drugs, leaving clinical needs largely unmet.
GPN01564 is a key product reserve within the Group's anti-infective innovation platform in the respiratory and critical and severe disease segment. Centred on the Wuhan Optics Valley international R&D centre, which covers more than 13,000 sqm, the platform has projects under way in RSV, sepsis, acute respiratory distress syndrome, influenza, herpes virus, COVID-19 and Gram-negative bacteria. The Group cautioned that the product remains at the R&D stage and that approval for marketing and ultimate returns are subject to significant uncertainty.
- GRANDPHARMA (00512.HK): Six Products Join Reimbursement and Commercial Insurance Lists
- GRANDPHARMA (00512.HK): GPN01020 Phase II enrols first patient
- GRANDPHARMA (00512.HK): Innovative RDC Drug GPN01530-2 Granted FDA Fast Track Designation for Diagnosis of Solid Tumors
- Grand Pharmaceutical (00512.HK): TCM Class 1.1 Innovative Drug GPN01360 Completes First Patient Enrollment in Phase III Depression Study